JP Morgan Chase
ENTA icon

JP Morgan Chase’s Enanta Pharmaceuticals ENTA Stock Holding History

JP Morgan Chase’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-27,000
Closed -$2.31M – 5737
2018
Q3 		$2.31M Sell
27,000
-3,000
-10% -$301K ﹤0.01% 3358
2018
Q2 		$3.48M Buy
+30,000
New +$2.99M ﹤0.01% 2975

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

JP Morgan Chase's ENTA Position: Q1 2026 in Review

JP Morgan Chase reduced its Enanta Pharmaceuticals (ENTA) stake by 8.8% in Q1 2026, selling an estimated $133K and leaving 103,059 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #4449.

JP Morgan Chase first reported a position in ENTA in Q1 2015 and has held it in 42 quarters since. The position peaked at $9.76M in Q4 2017. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • JP Morgan Chase held 103,059 shares of Enanta Pharmaceuticals worth $1.26M as of Q1 2026.
  • JP Morgan Chase sold 9,905 Enanta Pharmaceuticals shares in Q1 2026, an estimated $133K.
  • Enanta Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #4449 holding.
  • JP Morgan Chase first reported a position in Enanta Pharmaceuticals in Q1 2015 and has held it in 42 quarters since.
  • JP Morgan Chase's Enanta Pharmaceuticals position peaked at $9.76M in Q4 2017.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.